Cybin Inc. provided an update on its clinical-stage programs and key upcoming milestones across its development pipeline. Upcoming clinical milestones: CYB003 - Deuterated Psilocybin Analog Program. Complete Phase 2 topline safety and efficacy data readout for CYB003 in MDD, including 6-week data and results on the incremental benefit of a second dose expected in fourth quarter of 2023.

Submission of topline data to U.S. Food and Drug Administration ("FDA") following readout, for an end of Phase 2 meeting in early 2024. Additional Phase 2 data assessing durability of effect for CYB003 at 12 weeks expected in first quarter of 2024. Progression to an international, multisite Phase 3 trial in early 2024 to further evaluate the safety and efficacy of CYB003 capsules in a larger MDD patient population, with recruiting expected to begin by end of first quarter of 2024.

Deuterated DMT Program: Phase 1 dosing, pharmacokinetic ("PK") and pharmacodynamic ("PD"), and safety data for CYB004 and SPL028 expected in fourth quarter of 2023. Initiate Phase 2 proof-of-concept study in participants with generalized anxiety disorder in first quarter of 2024. A CYB004 subcutaneous formulation study in first quarter of 2024 in addition to the SPL028 formulation work.